Skaana Management’s Ginkgo Bioworks DNA Stock Holding History

Skaana Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-475	Closed	-$45K	–	113
2022 Q2	$45K	Buy	+475	New	+$57.9K	0.01%	72

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Skaana Management's DNA Position: Q3 2022 in Review

Skaana Management sold out of Ginkgo Bioworks (DNA) in Q3 2022, closing a stake of 475 shares — an estimated $45K sold.

Skaana Management first reported a position in DNA in Q2 2022 and held it in 1 quarter. The position peaked at $45K in Q2 2022. 278 funds tracked by Wall St. Rank hold DNA as of Q3 2022.

Skaana Management reported no remaining Ginkgo Bioworks position as of Q3 2022 after selling out during the quarter.
Skaana Management sold 475 Ginkgo Bioworks shares in Q3 2022, an estimated $45K.
Skaana Management first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 1 quarter.
Skaana Management's Ginkgo Bioworks position peaked at $45K in Q2 2022.
278 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2022.

Based on Skaana Management's 13F filing for Q3 2022, filed 10 Nov 2022.